Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Kamada Anti-SARS-CoV-2 · 1 trial · 2 indications
Record adverse events, serious adverse events, and deaths
| Arm | Type | Description |
|---|---|---|
| Immune gamma globulin (IgG) | EXPERIMENTAL | Single dose of 4g Immune gamma globulin (IgG) preparation Kamada Anti-SARS-CoV-2 given as an intravenous infusion |
| Name | Type | Description |
|---|---|---|
| Kamada Anti-SARS-CoV-2 | BIOLOGICAL | Anti-SARS-CoV-2 is a preparation of immune gamma globulin manufactured from convalescent plasma of COVID-19 recovered patients, using Kamada's proprietary purification methods |
Inclusion Criteria: 1. Age ≥ 18 years 2. Laboratory confirmed SARS-CoV-2 infection by nasopharyngeal swab Real time polymerase chain reaction (RT-PCR) 3. Hospitalized for COVID-19 pneumonia 4. Dosing should be within 10 days of symptom start 5. Able and willing to sign informed consent form Exclus...
Kamada Anti-SARS-CoV-2 is an investigational monoclonal antibody being developed for COVID-19. It is intended to treat the viral infection and associated pneumonia caused by SARS-CoV-2. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
Kamada Anti-SARS-CoV-2 is being developed by Kamada Ltd., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KMDA. The company is conducting clinical trials to evaluate the safety and pharmacokinetics of this monoclonal antibody in patients with COVID-19.
Kamada Anti-SARS-CoV-2 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It is not approved for commercial use, and further clinical studies would be needed to establish its safety and efficacy.
Kamada Anti-SARS-CoV-2 has one completed Phase 1 trial, registered as NCT04550325, titled "Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19." The study enrolled 12 participants in Israel and evaluated the drug's safety, pharmacokinetics, and pharmacodynamics in patients with COVID-19 and viral pneumonia.
Kamada Anti-SARS-CoV-2 is a monoclonal antibody designed to target the SARS-CoV-2 virus, the pathogen that causes COVID-19. By binding to the virus, the antibody is intended to neutralize it and prevent it from infecting human cells, potentially reducing viral load and disease severity.